A Ketamine-Based Nasal Spray For Depression Has Just Been Approved by The FDA
The Food and Drug Administration approved a novel antidepressant late Tuesday for people with depression that does not respond to other treatments – the first in decades to work in a completely new way in the brain.
The drug, a nasal spray called esketamine, has been eagerly anticipated by psychiatrists and patient groups as a powerful new tool to fight intractable depression.
The spray acts within hours, rather than weeks or months as is typical for current antidepressants, and could offer a lifeline to about 5 million people in the United States with major depressive disorder who haven’t been helped by current treatments. That accounts for about 1 in 3 people with depression.
What is SPRAVATO (esketamine) Nasel Spray?
SPRAVATOTM is a prescription medicine, used along with an antidepressant taken by mouth, for treatment-resistant depression (TRD) in adults.
SPRAVATOTM is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATOTM is safe or effective as an anesthetic medicine. Read more
For more information about Ketamine Infusion Therapy treatments for depression, bipolar, anxiety, post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), fibromyalgia, pain syndromes and other conditions contact us at Ketamine Clinics of Los Angeles in Southern California (Orange County) by clicking here or calling 310-270-0625.